Latest News

uniQure’s Hemgenix Royalty Sales Agreement Extends Cash Runway, Relieves Near-Term Commercial Risk, Says Analyst

uniQure N.V. (NASDAQ: QURE) agreed to sell a portion of the royalty rights due from CSL Behring from Hemgenix (etranacogene dezaparvovec-drbl) net sales to HealthCare Royalty and Sagard Healthcare read more

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News